News | August 30, 2011

Accuray Drives Growth in Radiosurgery for Early Stage Prostate Cancer

August 30, 2011 — Accuray Inc. announced a significant increase in use of the CyberKnife Robotic Radiosurgery System for prostate SBRT (stereotactic body radiotherapy). In Q4 2011, the company experienced a 24 percent increase in worldwide prostate treatments over Q4 2010 and a 17 percent increase over Q3 2011.

Earlier in 2011, Accuray announced the first publication from the expanding foundation of maturing prostate SBRT long-term studies documenting five-year outcomes of prostate cancer patients treated with the CyberKnife system. The multi-center study combines data from patients at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla. It found 93 percent of patients had no recurrence of their cancer at a median follow-up of five years. That rate compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy.

The study also found generally low levels of urinary and rectal toxicity, concluding that CyberKnife SBRT can achieve high rates of disease control while sparing critical structures; this minimizes undesirable side effects typically associated with other prostate cancer treatments and preserving patients' quality of life.

Adding to the growing body of evidence is the completion of patient accrual in an Accuray-sponsored, multi-center homogeneous prostate study for low and intermediate risk prostate cancer. The study consists of teams at the Swedish Cancer Center in Seattle and the Beth Israel Deaconess Medical Center in Boston and involves 21 centers in the United States. A total of 309 eligible patients have been accrued and are being followed closely to allow precise evaluation of the long-term efficacy and toxicity outcomes following CyberKnife prostate SBRT.

Michael Kendrick, M.D., a practicing physician familiar with radiosurgery, was the first patient in the world to undergo CyberKnife prostate SBRT and was treated in 2003 at Stanford.

"After learning about the CyberKnife and drawing on my expertise as a physician, deciding to move forward with CyberKnife prostate SBRT was a no brainer," said Kendrick. "CyberKnife's pinpoint accuracy and ability to track and correct for prostate motion was an important factor in my decision. I experienced no side effects, a fast recovery time, and was able to maintain a high quality of life during and following treatment. My PSA level has remained stable proving to me that CyberKnife SBRT was an effective treatment, a choice I have never regretted."

The system is a non-invasive treatment option for prostate cancer with the ability to deliver targeted and destructive doses of radiation at high accuracy, enabling treatment of tumors close to critical, healthy structures. Its unique ability to not only track but automatically correct for unpredictable movement of the prostate during treatment minimizes radiation exposure to health tissues; it also helps patients avoid many side effects typically associated with other treatment options, preserving quality of life.

Accuray continues to support patient education, including awareness of all treatment options. The company also supports access to innovation and high quality care through partnerships with leading non-profit prostate cancer organizations, including:

- Us TOO International Prostate Cancer Education & Support Network

Founded in 1990 by five men treated for prostate cancer, Us TOO is a grassroots, registered 501(c)(3) non-profit prostate cancer education and support network of 325 support group chapters worldwide. The organization's mission is to provide men and their families with free information, materials and peer-to-peer support to make informed choices on detection, treatment options and coping with ongoing survivorship. Accuray recently collaborated with Us TOO on a new, comprehensive information guide addressing what every newly diagnosed prostate cancer patient needs to know about treatment with the CyberKnife system.

- ZERO — The Project to End Prostate Cancer

ZERO is committed not only to reducing prostate cancer and alleviating pain from the disease, but to ending it altogether. The organization provides comprehensive treatment information to patients, education to those at risk and free prostate cancer testing. In addition, ZERO works to increase funds from the federal government for research into new treatments. It also provides local grants to end prostate cancer through its national race and event series, the Great Prostate Cancer Challenge.

For more information: www.accuray.com

Related Content

RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Overlay Init